Literature DB >> 26719485

What to do when people with Parkinson's disease cannot take their usual oral medications.

Jane Alty1, Jeremy Robson2, Philippa Duggan-Carter3, Stuart Jamieson1.   

Abstract

People with Parkinson's disease have limited brain reserves of endogenous dopamine; thus, their medications must not be omitted or delayed as this may lead to a significant drop in brain dopamine levels. This has two main clinical consequences: first, a deterioration in disease control, with distressing symptoms such as tremor, pain, rigidity, dysphagia and immobility, and second, an increased risk of developing the life-threatening complication of neuroleptic malignant-like syndrome. Common reasons for people with Parkinson's disease being unable to take their oral medications are neurogenic dysphagia from progressive disease or concurrent illness, gastroenteritis, iatrogenic 'nil by mouth' status especially perioperatively, and impaired consciousness level. Here we outline alternative methods to give dopaminergic drugs in the acute setting to people with Parkinson's disease who cannot take their usual oral treatment, namely using dispersible preparations in thickened fluids, an enteral tube, a transdermal patch or subcutaneous injections. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  DYSPHAGIA; MOVEMENT DISORDERS; NEUROPHARMACOLOGY; PARKINSON-S DISEASE; PHARMACOLOGY

Mesh:

Substances:

Year:  2015        PMID: 26719485     DOI: 10.1136/practneurol-2015-001267

Source DB:  PubMed          Journal:  Pract Neurol        ISSN: 1474-7758


  4 in total

1.  Update on the diagnosis and management of Parkinson's disease.

Authors:  Christopher Kobylecki
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

2.  Pharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects.

Authors:  Wenjia Zhou; Chengzhe Lv; Quanying Zhang; Shunlin Zong; Meng Wang
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

Review 3.  Emergencies and critical issues in Parkinson's disease.

Authors:  Cristina Simonet; Eduardo Tolosa; Ana Camara; Francesc Valldeoriola
Journal:  Pract Neurol       Date:  2019-08-19

Review 4.  Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience.

Authors:  Vanessa Raeder; Iro Boura; Valentina Leta; Peter Jenner; Heinz Reichmann; Claudia Trenkwalder; Lisa Klingelhoefer; K Ray Chaudhuri
Journal:  CNS Drugs       Date:  2021-02-09       Impact factor: 5.749

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.